424B3424B3
Jun 2, 2026Final prospectus0001104659-26-069146
All companies
Trade Cellectar Biosciences Inc424B4Jul 2, 2025
Cellectar Biosciences, Inc. S-1 (resale) filed for up to 51,206,051 shares of common stock (selling stockholders)
Cellectar Biosciences Inc
CLRBPublicArchived
Public / ArchivedUnited States(Nasdaq)Best valuation $20.54M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
CLRBPrice
$2.57
24h
-7.89%
Valuation
$20.54M
24h volume
$246.78K
Type
IPO
Trade Cellectar Biosciences IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Cellectar Biosciences Inc IPO public float & lock-up
Public float and locked shares extracted from Cellectar Biosciences Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
2.68M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001279704.
Revenue
—
Net income
-$21.79M
Gross margin
—
Cash
$13.2M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$22.98M | -$51.78M | -$38.96M | -$28.81M | -$24.13M |
| Net income | -$21.79M | -$44.58M | -$37.98M | -$31.79M | -$24.12M |
| R&D expense | $11.5M | $26.14M | $27.27M | $18.27M | $17.59M |
| Cash & equivalents | $13.2M | $23.29M | $9.56M | $19.87M | $35.7M |
| Total assets | $14.98M | $25.47M | $12.08M | $21.59M | $37.2M |
| Total liabilities | $5.06M | $9.8M | $25.85M | $12.05M | $4.16M |
| Shareholders' equity | $8.54M | $14.29M | -$15.16M | $8.15M | $29.06M |
About Cellectar Biosciences Inc
Cellectar Biosciences Inc is a healthcare and life-sciences company with a business profile centered on medical products, therapies, diagnostics, or health-related services.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Cellectar Biosciences Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
Final prospectusEDGAR filings resolved from CLRB / CIK 0001279704.
Jun 1, 2026Effective9999999995-26-001826
S-1/AFORM S-1/A
May 29, 2026Amended0001104659-26-067933
S-1FORM S-1
May 19, 2026Filed0001104659-26-063918
424B3424B3
Nov 21, 2025Final prospectus0001104659-25-114989
S-1FORM S-1
Oct 20, 2025Filed0001104659-25-100854
424B4424B4
Jul 2, 2025Final prospectus0001104659-25-064897
Jul 1, 2025Effective9999999995-25-002137
CORRESPfilename1.htm
Jun 30, 2025SEC correspondence0001104659-25-063941
CORRESPfilename1.htm
Jun 30, 2025SEC correspondence0001104659-25-063940
S-1/AFORM S-1/A
Jun 30, 2025Amended0001104659-25-063849
S-1FORM S-1
Jun 26, 2025Filed0001104659-25-062834
Latest Cellectar Biosciences Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
U.S. SEC (EDGAR)May 19, 2026IPO filing
Cellectar Biosciences filed a Form S-1 (as filed May 19, 2026) covering the resale, from time to time, by selling stockholders of up to 51,206,051 shares of common stock, including shares issued and shares issuable upon warrant exercises related to a private placement that closed on May 6, 2026.
Cellectar Biosciences Inc IPO — frequently asked questions
- When did Cellectar Biosciences Inc go public?
- Cellectar Biosciences Inc has already gone public and now trades publicly on Nasdaq under the ticker CLRB.
- Can I buy Cellectar Biosciences Inc stock?
- Yes — Cellectar Biosciences Inc is publicly traded on Nasdaq as CLRB. You can follow its live price, valuation and post-IPO performance above.
- What is Cellectar Biosciences Inc's valuation?
- Cellectar Biosciences Inc's most recent valuation tracked here is $20.54M, derived from live market prices.